Following a deep understanding of disease biology, SphingoTec has developed novel biomarkers addressing diagnostically underserved critical care conditions. SphingoTec identified major pathways…
Scientific Publications
Browse our scientific publications to learn more about how our biomarkers can impact patient care.
Learn more
Downloads
Discover our brochures, product cataloge and white…
Privacy Policy
1. An overview of data protection
General information
The following information will provide you with an easy to navigate overview of what will happen with your personal data when…
SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury.
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers. These tests allow for the diagnosis, outcome prediction, and…
Disclaimer & Privacy notice
The information provided in this quote request will be forwarded to the distributors responsible for your area. Products based on the Nexus IB10 technology…
SphingoTec announces a series of presentations demonstrating the utility of its innovative biomarkers in sepsis, positively impacting diagnostic and treatment decisions for critically ill patients.